Series D for dental drugs: C3 Jian raises $60m
This article was originally published in Scrip
Executive Summary
C3 Jian has an unconventional set of venture capital investors, but the company also has a unique set of products candidates: peptide-based antimicrobials to prevent and treat tooth decay from a microbiome-targeting drug discovery platform.